Cardiovascular Division, Departments of Medicine and Radiology and the Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, VA 22908, USA.
J Nucl Cardiol. 2012 Apr;19(2):377-88. doi: 10.1007/s12350-012-9512-2.
Cardiotoxicity due to administration of cancer therapeutic agents such as anthracyclines and herceptin are well described. Established guidelines to screen for chemotherapy-related cardiotoxicity (CRC) are primarily based on serial assessment of left ventricular (LV) ejection fraction (EF). However, other parameters such as LV volume, diastolic function, and strain may also be useful in screening for cardiotoxicity. More recent advances in molecular imaging of apoptosis and tissue characterization by cardiac MRI are techniques which might allow early detection of patients at high risk for developing cardiotoxicity prior to a drop in EF. This comprehensive multi-modality review will discuss both the current established imaging techniques as well as the emerging technologies which may revolutionize the future of screening and evaluation for CRC.
由于癌症治疗药物(如蒽环类药物和赫赛汀)的使用而导致的心脏毒性已得到充分描述。用于筛查化疗相关性心脏毒性(CRC)的既定指南主要基于左心室(LV)射血分数(EF)的连续评估。然而,LV 容积、舒张功能和应变等其他参数也可能有助于筛查心脏毒性。心脏 MRI 通过分子成像对细胞凋亡和组织特征进行更深入的研究,这些技术可能会在 EF 下降之前允许早期检测出发生心脏毒性风险较高的患者。本综述将全面讨论当前已建立的成像技术以及可能彻底改变 CRC 筛查和评估未来的新兴技术。